Innovative Medicines and Medical Technology Review

Department of Health written question – answered on 13th November 2017.

Alert me about debates like this

Photo of Jim Shannon Jim Shannon Shadow DUP Spokesperson (Human Rights), Shadow DUP Spokesperson (Health)

To ask the Secretary of State for Health, what assessment he has made of the capacity of the Accelerated Access Pathway to consider treatments for rare diseases, including muscle-wasting conditions, to be considered for fast-track breakthrough designation.

Photo of Steve Brine Steve Brine The Parliamentary Under-Secretary of State for Health

The Accelerated Access Collaborative (AAC) will define the criteria for breakthrough products in the coming months. As set out in the response to the Accelerated Access Response, the AAC will focus on affordable products which can dramatically improve efficiency, fill an unmet need or make a step change in patient outcomes.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.